Table of Contents
Cardiovascular diseases (CVDs) remain one of the leading causes of death worldwide. According to data released by the World Health Organization (WHO) in 2023, cardiovascular diseases cause approximately 17.9 million deaths annually, accounting for 32% of all global deaths.
Consequently, the market demand for cardiovascular drug intermediates, a critical upstream component, has expanded significantly.
Today, based on publicly available data, regulatory guidelines, and industry research reports, we will comprehensively analyze the key compound types, market trends, and supply chain demands of cardiovascular drug intermediates, providing decision-making support for procurement, R&D, and CDMO partners.
Cardiovascular drugs, represented by antihypertensives, lipid-lowering drugs, and antithrombotic drugs, are one of the most stable and continuously growing markets globally.
According to the IQVIA “Global Use of Medicines 2023” report, global sales of cardiovascular system drugs exceeded US$160 billion in 2022–2023, and are expected to maintain a compound annual growth rate (CAGR) of 3–6% until 2027.
The core structures of these drugs often require complex chemical intermediates, occupying a critical position in multi-step synthesis routes.
In recent years, several innovative cardiovascular drugs have been launched or entered late-stage clinical trials, such as:
These varieties typically involve complex intermediate processes such as multi-functional groups, asymmetric synthesis, chiral resolution, and catalytic hydrogenation, driving the demand for high-value-added intermediate suppliers.
According to CPhI Insights 2022 data, the Asian region, especially China and India, accounts for more than 60% of the global API and intermediate production share. As Europe and the US strengthen their supply chain diversification strategies, more and more pharmaceutical companies are seeking intermediate partners with GMP certification, scalability, and compliance capabilities, leading to increased market demand.
Cardiovascular system drugs cover multiple therapeutic areas, including antihypertensives, lipid-lowering agents, antithrombotics, anti-heart failure drugs, and antiarrhythmics. Their core intermediates can be independently categorized as follows:
Statins remain the most widely used lipid-lowering drugs globally. Their synthesis routes typically include:
Construction of lactone structures
Common intermediates include:
Demand driver: Long-term sustained demand for cardiovascular disease prevention and treatment globally.
Representative drugs: Telmisartan, Valsartan, Irbesartan, Olmesartan, etc.
Requires strict control of impurities (especially NDMA-type impurities, which have received attention in recent years)
Typical intermediates include:
Demand driver: The number of hypertension patients worldwide continues to grow (WHO 2023 data: over 1.2 billion people).
Including anticoagulants and antiplatelet drugs, such as:
Related intermediates usually have:
Such as the key intermediate for rivaroxaban, 5-Chloro-2-methoxy-4-nitroaniline.
Demand driver: Significant global increase in diseases such as myocardial infarction, stroke, and atrial fibrillation.
Such as sacubitril/valsartan (Entresto). Their intermediates often feature:
Demand driver: The number of heart failure patients is increasing annually (AHA 2022 estimates approximately 6.4 million people in the US have heart failure).
Especially after the NDMA impurity incident, global regulatory agencies have strengthened their scrutiny of intermediate purity and process routes.
The FDA and EMA both require:
Intermediate suppliers need to have a complete QA/QC system.
Overseas pharmaceutical companies generally require:
This places higher demands on the supplier’s engineering capabilities.
Multiple innovative drug projects globally are entering clinical trials, driving the growth of intermediate demand from kilograms to tons.
The cooperation model between CDMOs and intermediate manufacturing companies is becoming more stable and long-term.
For pharmaceutical companies, evaluating intermediate suppliers requires focusing on the following capabilities:
Including reaction vessel capacity, continuous flow, hydrogenation, and other process capabilities.
Whether it meets ICH and GMP requirements, and whether it has consistent batch production experience.
Therefore, we can conclude that against the backdrop of continuously expanding global demand for cardiovascular disease drugs, the market demand for cardiovascular drug intermediates will continue to maintain strong growth.
If you are looking for a reliable partner for cardiovascular drug intermediates, please visit our product lists.
Email: suqnian0123@gmail.com
WhatsApp: +86 17663713557
Why more pharma companies outsource intermediate manufacturing is no longer just a cost question. Based on real project experience, this article explains how outsourcing intermediates helps drug developers improve speed, manage impurity risk, and maintain regulatory control while focusing on core innovation.
This article shares practical, field-based experience on designing robust analytical methods for complex intermediates, focusing on impurity identification, method robustness, and regulatory expectations.
The Rise of High-Potency Intermediates highlights a fundamental shift in pharmaceutical manufacturing, where potency-related risks emerge early at the intermediate stage. As oncology and targeted therapies expand, manufacturers must integrate exposure control, impurity strategy, and scalable process design to ensure compliance, safety, and long-term supply reliability.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.